Skip to content

Defining the Role of Marginal Zone B Cells in FVIII Inhibitor Development.

2026 · Methods in molecular biology · Vol 3053, pp. 823-835 · 0 citations
Medicine

TL;DR

The interactions between MZ B cells, CD4 T cells, and other immune components in the spleen are investigated, providing a deeper understanding of the molecular mechanisms underlying FVIII inhibitor development.

View source

Similar papers

Open access Aug 2026

CD137 agonists in mice suppress germinal center responses by increasing the immunosuppressive activity of follicular regulatory T-cells

Humoral immune responses rely on germinal center (GC) reactions to generate long-lasting antibody responses with affinity maturation. CD137 (4-1BB) agonists are known to exert inhibitory effects on B-cell responses; however, the underlying mechanisms remain unclear. Here, we show that agonistic anti-CD137 monoclonal an...

Ana Martínez-Riaño, Raquel Cuesta, Dayanna Salinas et al. · 0 citations
Review Aug 2026

B-cell depletion therapy in systemic lupus erythematosus: emerging strategies and challenges

ABSTRACT Introduction B cell plays a pivoting role in the pathogenesis of systemic lupus erythematosus (SLE). In addition to the production of autoantibodies, B cells present antigens to activate the T cells and release proinflammatory cytokines that are relevant for disease activity. B cell modulation remains the spot...

Tsz-Ching Mok, C. Mok · 0 citations
Open access Oct 2026

CO-39 | MYELOID CELL FUNCTION AND CYTOKINE PROFILES IN PEDIATRIC HEMOPHILIA A: INSIGHTS FROM FACTOR VIII AND EMICIZUMAB PROPHYLAXIS

Background and Aims. Haemophilia A (HA) is an X-linked bleeding disorder caused by factor VIII (FVIII) deficiency, treated with FVIII infusions or, more recently, emicizumab subcutaneously. Although emicizumab is safe and effective, FVIII is still required for severe bleeding, trauma, or surgery, and few studies have c...

Tiziano Martini · 0 citations
Review Open access Aug 2026

The PVR-TIGIT/CD96/CD226 axis: a novel immune checkpoint target in ovarian cancer

The structure, function, and receptor interactions of CD155 (PVR), with a particular focus on its immunoregulatory role in the ovarian tumor microenvironment are reviewed.

Ming-Yao Huang, Jia-Hui Zhang, Hui-Yan Huang et al. · 0 citations
Open access Sep 2026

Teclistamab for the treatment of autoantibody-mediated coagulation disorders.

BACKGROUND Teclistamab is a bispecific monoclonal antibody that targets B cell maturation antigen (BCMA) on plasma cells and other B lineage cells and CD3 on T cells, thereby redirecting cytotoxic T cells to eliminate BCMA-expressing antibody-producing cells. Autoantibody-mediated coagulation disorders are often driven...

Johannes Thaler, K. Gleixner, L. Eischer et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.